SPRB
Spruce Biosciences, Inc.
Biotechnology
Market Cap$78M
5Y Perf.-96.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SPRB vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-74.0%
SPRB vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SPRB | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $78M | $2.57B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-39M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $736K | $1.28B |
| Cash & Equiv. | $49M | $434M |
SPRB vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SPRB
RARE
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Spruce Biosciences,… (SPRB) | 100 | 3.4 | -96.6% |
| Ultragenyx Pharmace… (RARE) | 100 | 26.0 | -74.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SPRB vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SPRB leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SPRB
Spruce Biosciences, Inc.
The Income Pick
SPRB carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.75
- Lower volatility, beta 0.75, Low D/E 1.7%, current ratio 5.17x
- Beta 0.75, current ratio 5.17x
Best for: income & stability and sleep-well-at-night
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Play
RARE is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 20.1%, EPS growth 7.3%, 3Y rev CAGR 22.8%
- -59.4% 10Y total return vs SPRB's -95.6%
- 20.1% revenue growth vs SPRB's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs SPRB's -100.0% |
| Quality / Margins | SPRB | -0.2% margin vs RARE's -91.0% |
| Stability / Safety | SPRB | Beta 0.75 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SPRB | +9.3% vs RARE's -21.8% |
| Efficiency (ROA) | RARE | -45.8% ROA vs SPRB's -128.0% |
SPRB vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
SPRB vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRARELAGGINGSPRB
SPRBSpruce Biosciences, I…
0leads
RAREUltragenyx Pharmaceut…
3leads
6 Total Categories
CATEGORYLEADERvs SPRBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
RARE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RARE4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RARE5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SPRB and RARE each lead in 1 of 2 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE and SPRB operate at a comparable scale, with $669M and $0 in trailing revenue. On growth, RARE holds the edge at -2.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SPRBSpruce Bioscience… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$36M | -$536M |
| Net IncomeAfter-tax profit | -$39M | -$609M |
| Free Cash FlowCash after capex | -$33M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +75.5% | -17.2% |
Evenly matched — SPRB and RARE each lead in 1 of 2 comparable metrics.
Valuation Metrics
RARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | SPRBSpruce Bioscience… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $78M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $29M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.11x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.82x |
| Price / BookPrice ÷ Book value/share | 1.02x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
RARE leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
SPRB delivers a -2.0% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs SPRB's 3/9, reflecting mixed financial health.
| Metric | SPRBSpruce Bioscience… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -2.0% | -6.1% |
| ROA (TTM)Return on assets | -128.0% | -45.8% |
| ROICReturn on invested capital | — | -89.4% |
| ROCEReturn on capital employed | -100.2% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$48M | $842M |
| Cash & Equiv.Liquid assets | $49M | $434M |
| Total DebtShort + long-term debt | $736,000 | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -392.62x | -14.49x |
RARE leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RARE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RARE five years ago would be worth $2,281 today (with dividends reinvested), compared to $489 for SPRB. Over the past 12 months, SPRB leads with a +932.3% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors RARE at -17.8% vs SPRB's -30.7% — a key indicator of consistent wealth creation.
| Metric | SPRBSpruce Bioscience… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -37.6% | +10.7% |
| 1-Year ReturnPast 12 months | +932.3% | -21.8% |
| 3-Year ReturnCumulative with dividends | -66.8% | -44.5% |
| 5-Year ReturnCumulative with dividends | -95.1% | -77.2% |
| 10-Year ReturnCumulative with dividends | -95.6% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -30.7% | -17.8% |
RARE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SPRB and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
SPRB is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 61.7% from its 52-week high vs SPRB's 23.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SPRBSpruce Bioscience… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 1.42x |
| 52-Week HighHighest price in past year | $240.00 | $42.37 |
| 52-Week LowLowest price in past year | $4.35 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +23.6% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 46.4 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 61K | 1.8M |
Evenly matched — SPRB and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SPRBSpruce Bioscience… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $51.50 |
| # AnalystsCovering analysts | — | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallUltragenyx Pharmaceutical I… (RARE)Leads 3 of 6 categories
Loading custom metrics...
SPRB vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SPRB or RARE a better buy right now?
For growth investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Spruce Biosciences, Inc. (SPRB). Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SPRB or RARE?
Over the past 5 years, Ultragenyx Pharmaceutical Inc.
(RARE) delivered a total return of -77. 2%, compared to -95. 1% for Spruce Biosciences, Inc. (SPRB). Over 10 years, the gap is even starker: RARE returned -59. 4% versus SPRB's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SPRB or RARE?
By beta (market sensitivity over 5 years), Spruce Biosciences, Inc.
(SPRB) is the lower-risk stock at 0. 75β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 89% more volatile than SPRB relative to the S&P 500.
04Which is growing faster — SPRB or RARE?
By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.
(RARE) is pulling ahead at 20. 1% versus -100. 0% for Spruce Biosciences, Inc. (SPRB). On earnings-per-share growth, the picture is similar: Spruce Biosciences, Inc. grew EPS 47. 5% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SPRB or RARE?
Spruce Biosciences, Inc.
(SPRB) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SPRB leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SPRB or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SPRB or RARE better for a retirement portfolio?
For long-horizon retirement investors, Spruce Biosciences, Inc.
(SPRB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Both have compounded well over 10 years (SPRB: -95. 6%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SPRB and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SPRB is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SPRB: -100.0% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.